NCT02768649View on ClinicalTrials.gov

Single Ascending Dose Study of RBP-7000

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Schizophrenia
Interventions
DRUG

RBP-7000

Sequential dosing of each cohort

DRUG

risperidone

All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.

Trial Locations (1)

08046

CRI Worldwide, Willingboro

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT02768649 - Single Ascending Dose Study of RBP-7000 | Biotech Hunter | Biotech Hunter